Abstract
The clinical courses, cerebrospinal fluid (CSF) and serum copper concentrations and urinary copper excretions under different schemes of drug treatment in four patients with cerebral manifestations of Wilson's disease were monitored over 6–11 years. CSF copper concentration measurements were performed from the beginning of therapy onwards in three patients and from 16 months after initial treatment onwards in the fourth. CSF copper levels decreased slowly over the years in parallel with clinical improvements, and increased in one patient who interrupted therapy for 2 years. These findings confirm our hypothesis that the concentration of copper in the CSF is a valuable quantitative parameter reflecting the normalization of copper in the brain. Copper measurements during phases of initial neurological deterioration in two patients receivingd-penicillamine, and in one patient receivingd-penicillamine and zinc sulphate, revealed decreased free serum copper and CSF copper levels.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Bachmann H, Lössner J, Kühne H-J, et al (1989) Long-term care and management of Wilson's disease in the GDR. Eur Neurol 29:301–305
Blake DR, Winyard P, Lunec J, Williams A, Good PA, Crewes SJ, Gutteridge JMC, Rowley D, Halliwell B, Cornish A, Hider RC (1985) Cerebral and ocular toxicity induced by desferrioxamine. Q J Med 56:345
Brewer GJ, Hill GM, Prasad AS, Cossack ZT, Rabbani P (1983) Oral zinc therapy for Wilson's disease. Ann Intern Med 99:314–320
Brewer GJ, Hill GM, Dick RD, Nostrant TT, Sams JS, Wells JJ, Prasad AS (1987) Treatment of Wilson's disease with zinc. III. Prevention of reaccumulation of hepatic copper. J Lab Clin Med 109:526–531
Brewer GJ, Hill G, Prasad A, Dick R (1987) The treatment of Wilson's disease with zinc. IV. Efficacy monitoring using urine, and plasma copper (42499). Proc Sop Exp Biol Med 184:446–455
Brewer GJ, Terry CA, Aisen AM, Hill GM (1987) Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy. Arch Neurol 44:490–493
Brewer GJ, Yuzbasiyan-Gurkan V (1989) Wilson's disease: an update, with emphasis on new approaches to treatment. Dig Dis 7:178–193
Brewer GJ, Yuzbasiyan-Gurkan V, Lee D-Y, Appelman H (1989) Treatment of Wilson's disease with zinc. VI. Initial treatment studies. J Lab Clin Med 114:633–638
Brewer GJ, Dick RD, Yuzbasiyan-Gurkan V, Tankanow R, Young AB, Kluin KJ (1991) Initial therapy of patients with Wilson's disease with tetrathiomolybdate. Arch Neurol 48:42–47
Dubois RS, Rodgerson DO, Hambidge KM (1990) Treatment of Wilson's disease with triethylene tetramine hydrochloride (Trientine). J Pediatr Gastroenterol Nutr 10:77–81
Evenson MA, Warren BL (1975) Determination of serum copper by atomic absorption, with use of graphite cuvette. Clin Chem 21:619–625
Frydman M, Bonne-Tamir B, Farrer LA, et al (1985) Assignment of the gene for Wilson's disease to chromosome 13. Linkage to the esterase D locus. Proc Natl Acad Sci USA 82:1819–1821
Glass JD, Reich SG, DeLong MR (1990) Wilson's disease. Development of neurological disease after beginning penicillamine therapy. Arch Neurol 47:595–596
Grimm G, Oder W, Prayer L, Ferenci P, Madl C (1990) Evoked potentials in assessment and follow-up of patients with Wilson's disease. Lancet 336:963–964
Hill G, Brewer GJ, Juni JE, Prasad AS, Dick RD (1986) Treatment of Wilson's disease with zinc. II. Validation of Oral64copper with copper balance. Am J Med Sci 292:344–349
Hill GM, Brewer GJ, Prasad AS, Hydrick CR, Hartmann D (1987) Treatment of Wilson's disease with zinc. I. Oral zinc therapy regimens. Hepatology 8:522–528
Hilz MJ, Druschky K-F, Bauer J, Neundörfer B, Schuierer G (1990) Morbus Wilson — kritische Verschlechterung unter hochdosierter parenteraler Penicillamin-Therapie. Dtsch Med Wochenschr 115:93–97
Hoogenraad TU, Van den Hamer CJA (1983) 3 years of continous oral zinc therapy in 4 patients with Wilson's disease. Acta Neurol Scand 67:356–364
Hoogenraad TU, Van Hattum J, Van den Hamer CJA (1987) Management of Wilson's disease with zinc sulphate. Experience in a series of 27 patients. J Neurol Sci 77:137–146
Kodama H, Okabe I, Yanagisawa M, Nomiyama H, Nomiyama K, Nose O, Kamoshita S (1988) Does CSF copper level in Wilson disease reflect copper accumulation in the brain. Pediatr Neurol 4:35–37
Laurell CB (1965) Antigen antibody crossed electrophoresis. Anal Biochem 10:358–361
Lee D-Y, Brewer GJ, Wang Y (1989) Treatment of Wilson's disease with zinc. VII. Protection of the liver from copper toxicity by zinc-induced metallothionein in a rat model. J Lab Clin Med 114:639–646
Lößner A, Lößner J, Bachmann H, et al (1986) The Kayser-Feischer ring during long-term treatment in Wilson's disease (hepatolenticular degeneration): a follow-up study. Graefe's Arch Clin Exp Ophthalmol 224:152–155
Mason J, McQuaid A, Pheiffer H (1989) Can Wilson's disease patients be decoppered? Lancet 1:1455
Mayet IY (1990) Low-dose zinc therapy for maintenance treatment of Wilson's disease. Clin Pharm 9:951–953
Müller-Jensen A, Zschocke S, Lachenmayer L (1983) Wilson's disease: Visual evoked responses in correlation with the clinical course. Electroencephalogr Clin Neurophysiol 56:139
Pall H, Blake DR, Good PA, Winyard P, Williams AC (1986) Copper chelation and the neuro-ophthalmic toxicity induced by desferrioxamine. Lancet II:1279
Pall HS, Williams AC, Blake DR (1989) Deterioration of Wilson's disease following the start of penicillamine therapy. Arch Neurol 46:359
Samman S (1987) The effect of zinc supplements on plasma zinc and copper levels and the reported symptoms in healthy volunteers. Med J Aust 146:246–249
Satishchandra P, Sathyanarayana, Swamy H (1989) Visual and brain stem auditory evoked responses in Wilson's disease. Acta Neurol Scand 79:108–113
Scheinberg IH, Sternlieb I (1984) Wilson's disease. In: Smith LH (ed) Major problems in internal medicine, vol XXIII. Saunders, Philadelphia, p 17
Scheinberg H, Jaffe ME, Sternlieb I (1987) The use of trientine in preventing the effects of interrupting penicillamine therapy in Wilson's disease. N Engl J Med 317:209–213
Scheinberg IH, Sternlieb I, Schilsky M, Stockert RJ (1987) Penicillamine may detoxify copper in Wilson's disease. Lancet 11:95
Schoen RE, Sternlieb I (1990) Clinical aspects of Wilson's disease. Am J Gastroenterol 85:1453–1457
Schoenberger M, Ellis PP (1979) Disappearance of Kayser-Fleischer rings after liver transplantation. Arch Ophthalmol 97:1914–1915
Starosta-Rubinstein S, Young AB, Kluin K, Hill G, Aisen A, Gabrielsen T, Brewer GJ (1987) Clinical assessment of 31 patients with Wilson's disease. Arch Neurol 44:365–370
Sternlieb I (1990) Perspectives on Wilson's disease. Hepatology 12:1234–1239
Sternlieb I, Scheinberg IH (1979) The role of radiocopper in the diagnosis of Wilson's disease. Gastroenterology 77:138–142
Van den Hamer CJA, Hoogenraad TU (1984)64Cu loading tests for monitoring zinc therapy in Wilson's disease. Trace Elem Med 1:84–87
Veen C, Van den Hamer CJA, Leeuw PW (1991) Zinc sulphate therapy for Wilson's disease after acute deterioration during treatment with low-dosed-penicillamine. J Intern Med 229:549–552
Volder A De, Sindic CJM, Goffinet AM (1988) Effect ofd-penicillamine treatment on brain metabolsm in Wilson's disease: a case study. J Neurol Neurosurg Psychiatry 51:947–949
Walshe JM (1956) Penicillamine. A new oral therapy for Wilson's disease. Am J Med 21:487–495
Walshe JM (1969) Management of penicillamine nephropathy in Wilson's disease. a new chelating agent. Lancet II:1401–1402
Walshe JM (1973) Copper chalation in patients with Wilson's disease. A comparison of penicillamine and triethylene tetramine dihydrochloride. Q J Med New Series XLII, No 167:441–452
Walshe JM (1982) Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride. Lancet I:643–647
Walshe JM (1986) The management of pregnancy in Wilson's disease treated with trientine. Q J Med 58, 225:81–87
Walshe JM (1986) Tetrathiomolybdate (MoSO4) as an anti-copper agent in man. In: Scheinberg IH, Walshe JM (eds) Orphan disease and orphan drugs. Manchester University Press, Manchester, pp 76–85
Walshe JM (1988) Wilson's disease: yesterday, today and tomorrow. Mov Disord 3:10–29
Walshe JM (1992) Thiomolybdates in the treatment of Wilson's disease. Arch Neurol 49:132
Weisner B, Hartard C, Dieu C (1987) CSF copper concentration: a new parameter for diagnosis and monitoring therapy of Wilson's disease with cerebral manifestation. J Neurol Sci 79:229–237
Wesch H, Przuntek H, Feist D (1980) Morbus Wilson. Rasche Diagnose und Differenzierung heterozygoter und homotygoter Anlageträger mit64CuCl2. Dtsch Med Wochenschr 105:483–488
Williams F, John B, Walshe JM (1981) Wilson's disease. An analysis of the cranial computerized tomographic appearances found in 60 patients and the changes in response to treatment with chelating agents. Brain 104:42–47
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hartard, C., Weisner, B., Dieu, C. et al. Wilson's disease with cerebral manifestation: monitoring therapy by CSF copper concentration. J Neurol 241, 101–107 (1993). https://doi.org/10.1007/BF00869772
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00869772